Výsledky vyhledávání

Inhibition of PDE4 Attenuates TNF-α-Triggered Cell Death Through Suppressing NF-κB and JNK Activation in HT-22 Neuronal Cells

Autor: Zhong-Zhen Zhou, Huizhen Wen, Rumeng Yao, Jiao Xiao, Jiangping Xu, Haitao Wang, Jiahong Zhong, Dan Li, Bingtian Xu

Publikováno v: Cellular and Molecular Neurobiology. 40:421-435

Tumor necrosis factor-α (TNF-α) is a critical pro-inflammatory cytokine regulating neuroinflammation. At high concentrations, it is toxic to neurons, and such damage is positively correlated with acute and chronic neurological diseases. Our previou

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66c6b86ae9f199e1490f5da24d3ef611
https://doi.org/10.1007/s10571-019-00745-w

Zobrazit plný text záznamu

Inhibition of PDE4 by FCPR16 induces AMPK-dependent autophagy and confers neuroprotection in SH-SY5Y cells and neurons exposed to MPP+-induced oxidative insult

Autor: Huizhen Wen, Jinfeng Xie, Jiangping Xu, Haitao Wang, Jiahong Zhong, Bingtian Xu, Zhong-Zhen Zhou, Dan Li, Jiao Xiao, Xinyi Wang, Yufang Cheng

Publikováno v: Free Radical Biology and Medicine. 135:87-101

The etiology of Parkinson's disease (PD) is generally not well understood, but it is believed to involve excessive oxidative insult. Hence, identifying therapeutic targets and compounds that exhibit protective effects against oxidative damage is a re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ee128983970b1499c9dbc1564c0bc866
https://doi.org/10.1016/j.freeradbiomed.2019.02.027

Zobrazit plný text záznamu

FCPR03, a novel phosphodiesterase 4 inhibitor, alleviates cerebral ischemia/reperfusion injury through activation of the AKT/GSK3β/ β-catenin signaling pathway

Autor: Haitao Wang, Zhong-Zhen Zhou, Wenli Dong, Huizhen Wen, Bingtian Xu, Xinyi Wang, Jiao Xiao, Yunyun Qin, Ningbo Cai, Tiantian Wang, Jiangping Xu

Publikováno v: Biochemical pharmacology. 163

Inhibition of phosphodiesterase 4 (PDE4) is a promising strategy for the treatment of ischemic stroke. However, the side effects of nausea and vomiting from the current PDE4 inhibitors have limited their clinical applications. FCPR03 is a novel PDE4

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d56c33807a7e6f216014df707d3154b7
https://pubmed.ncbi.nlm.nih.gov/30797872

Zobrazit plný text záznamu